Fujian Cosunter Pharmaceutical Co Ltd (300436) — Tangible Net Worth Ratio
Fujian Cosunter Pharmaceutical Co Ltd (300436) has a Tangible Net Worth Ratio of 36.4% as of March 2026. This metric is calculated by deducting intangible assets (CN¥200.97 Million) from net assets (CN¥316.18 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See working capital to net assets of Fujian Cosunter Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Fujian Cosunter Pharmaceutical Co Ltd Tangible Net Worth Ratio (2011–2025)
This chart shows how Fujian Cosunter Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 36.4%, reflecting net assets of CN¥316.18 Million with intangible assets of CN¥200.97 Million CNY. See Fujian Cosunter Pharmaceutical Co Ltd (300436) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Fujian Cosunter Pharmaceutical Co Ltd (2011–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Fujian Cosunter Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Fujian Cosunter Pharmaceutical Co Ltd market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 45.4% | CN¥346.30 Million | CN¥188.97 Million | CN¥1.40 Billion | ▲ +10.3 pp |
| 2024 | 35.1% | CN¥396.78 Million | CN¥257.49 Million | CN¥1.44 Billion | ▼ -12.7 pp |
| 2023 | 47.8% | CN¥569.24 Million | CN¥297.08 Million | CN¥1.61 Billion | ▼ -39.4 pp |
| 2022 | 87.2% | CN¥955.62 Million | CN¥122.28 Million | CN¥1.49 Billion | ▲ +0.9 pp |
| 2021 | 86.3% | CN¥1.05 Billion | CN¥144.21 Million | CN¥1.45 Billion | ▲ +12.0 pp |
| 2020 | 74.2% | CN¥581.99 Million | CN¥149.98 Million | CN¥1.01 Billion | ▲ +6.0 pp |
| 2019 | 68.2% | CN¥573.74 Million | CN¥182.19 Million | CN¥896.25 Million | ▼ -6.8 pp |
| 2018 | 75.1% | CN¥562.35 Million | CN¥140.14 Million | CN¥854.68 Million | ▼ -13.8 pp |
| 2017 | 88.9% | CN¥552.05 Million | CN¥61.52 Million | CN¥736.47 Million | ▼ -2.4 pp |
| 2016 | 91.2% | CN¥552.36 Million | CN¥48.57 Million | CN¥700.67 Million | ▼ -0.6 pp |
| 2015 | 91.8% | CN¥519.20 Million | CN¥42.36 Million | CN¥600.70 Million | ▲ +7.2 pp |
| 2014 | 84.7% | CN¥156.87 Million | CN¥24.04 Million | CN¥224.11 Million | ▲ +0.2 pp |
| 2013 | 84.5% | CN¥143.10 Million | CN¥22.20 Million | CN¥197.53 Million | ▲ +0.9 pp |
| 2012 | 83.6% | CN¥108.59 Million | CN¥17.84 Million | CN¥149.41 Million | ▼ -0.9 pp |
| 2011 | 84.4% | CN¥65.43 Million | CN¥10.18 Million | CN¥109.29 Million | — |